文献速递肿瘤 PET/CT骨显像与常规 SPECT

99mTc-MIP-1404 CZT SPECT/CT与68Ga-PSMA-11 PET/CT在高危前列腺癌初始分期中的头对头比较:一项II期研究

Head-to-head comparison of 99mTc-MIP-1404 CZT SPECT/CT and 68Ga/PSMA-11 PET/CT for primary staging of high-risk prostate cancer: a phase II study.
PubMed 文献 · EJNMMI Res · 2026-07-22

该II期研究纳入新诊断高危前列腺癌患者(年龄50-79岁,平均66岁),比较99mTc-MIP-1404 CZT SPECT/CT与68Ga-PSMA-11 PET/CT在转移检测中的效能。结果显示,99mTc-MIP-1404 CZT SPECT/CT对淋巴结和骨转移的患者水平灵敏度分别为81%和85%,特异性100%,基于该显像的治疗决策与PSMA PET/CT的一致率为91%(30/33)。

要点

  • 99mTc-MIP-1404 CZT SPECT/CT检测淋巴结和骨转移的灵敏度分别为81%和85%,特异性100%。
  • 99mTc-MIP-1404 CZT SPECT/CT对骨转移的灵敏度(85%)高于99mTc-HDP CZT SPECT/CT(57%)。
  • 基于99mTc-MIP-1404 CZT SPECT/CT的治疗决策与68Ga-PSMA-11 PET/CT一致率达91%。

核心结论

  • 99mTc-MIP-1404 CZT SPECT/CT在新诊断高危前列腺癌的转移分期和治疗计划中展现出较强的诊断能力,优于常规显像。
  • 尽管68Ga-PSMA-11 PET/CE-CT识别了更多额外病灶,但两种方法在治疗决策上的一致性仍然很高。
  • 考虑到99mTc-MIP-1404 CZT SPECT/CT更广泛的可及性,它可能成为PET/CT可用性有限环境下的实用替代方案。

研究设计与样本

  • II期研究纳入新诊断高危前列腺癌患者(年龄范围50-79岁,平均66岁),患者接受三种显像:99mTc-HDP CZT SPECT/CT、68Ga-PSMA-11 PET/CE-CT和99mTc-MIP-1404 CZT SPECT/CT。
  • 记录淋巴结和骨的转移受累情况,采用重复测量ANOVA和事后分析比较各模态性能。
  • 以PET扫描为参考标准,计算淋巴结和骨骼病灶的灵敏度和特异性,并比较基于两种显像的治疗决策。

主要发现

  • 99mTc-MIP-1404 CZT SPECT/CT在患者水平检测淋巴结转移的灵敏度为81%,检测骨转移的灵敏度为85%。
  • 99mTc-HDP CZT SPECT/CT检测骨转移的灵敏度为57%。
  • 99mTc-MIP-1404 CZT SPECT/CT无假阳性发现,与68Ga-PSMA-11 PET/CE-CT相比特异性为100%。
  • 在病灶水平分析中,99mTc-MIP-1404 CZT SPECT/CT对淋巴结转移的检出率显著高于CE-CT(p = 0.026),但显著低于68Ga-PSMA-11 PET/CE-CT(p = 0.003)。
  • 基于99mTc-MIP-1404 CZT SPECT/CT将转移负荷分类为高体积转移(HVM)和低体积转移(LVM)与68Ga-PSMA-11 PET/CE-CT的一致率为85%,而常规显像的一致率为64%。

关键数值与推荐

  • 99mTc-MIP-1404 CZT SPECT/CT基于的治疗决策与68Ga-PSMA-11 PET/CE-CT基于的决策在91%(30/33)的患者中一致。

临床怎么用

  • 对于新诊断高危前列腺癌患者,99mTc-MIP-1404 CZT SPECT/CT可用于转移分期和治疗计划,尤其在PET/CT可用性有限的机构可作为实用替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate whether 99mTc-MIP-1404 CZT SPECT/CT is non-inferior to 68Ga-PSMA-11 PET/CT for metastases detection in patients with newly diagnosed high risk prostate cancer (PCa). Patients with newly diagnosed high-risk PCa (age range 50-79 years, mean 66) underwent three imaging modalities: 99mTc-HDP CZT SPECT/CT, 68Ga-PSMA-11 PET/CE-CT (contrast-enhanced CT), and 99mTc-MIP-1404 CZT SPECT/CT. Metastatic involvement of lymph nodes (LN) and bones were recorded. Repeated-measures ANOVAs and post-hoc analyses were used to compare modality performance. Sensitivity and specificity for LN and skeletal lesions were calculated based on PET scans as the reference standard. 99mTc-MIP-1404 CZT SPECT/CT-based therapy decisions were compared to 68Ga-PSMA-11 PET/CT-based decisions. RESULTS: Sensitivity of 99mTc-MIP-1404 CZT SPECT/CT for metastasis detection at the patient level was 81% for LN metastasis and 85% for bone metastases, compared with 57% for bone metastases by 99mTc-HDP CZT SPECT/CT. There were no false positive findings by 99mTc-MIP-1404 CZT SPECT/CT; specificity was 100% compared to 68Ga-PSMA-11 PET/CE-CT. At lesion level analysis, 99mTc-MIP-1404 CZT SPECT/CT had significantly higher detection rate of LN metastases compared with CE-CT (p = 0.026), but a lower detection rate compared to 68Ga-PSMA-11 PET/CE-CT (p = 0.003). Classification of metastasis burden into high volume metastasis (HVM) and low volume metastasis (LVM) was concordant in 85% of cases based on 99mTc-MIP-1404 CZT SPECT/CT compared to 68Ga-PSMA-11 PET/CE-CT, while conventional imaging agreed in 64% of cases. Therapy decisions based on 99mTc-MIP-1404 CZT SPECT/CT were concordant with those based on 68Ga-PSMA-11 PET/CE-CT in 91% (30/33) of patients. CONCLUSIONS: 99mTc-MIP-1404 CZT SPECT/CT demonstrates strong diagnostic capability for metastatic staging and therapy planning in newly diagnosed high-risk PCa, outperforming conventional imaging. While 68Ga-PSMA-11 PET/CE-CT identified more additional lesions, concordance in treatment decisions remained high. Considering its broader accessibility, 99mTc-MIP-1404 CZT SPECT/CT may represent a practical alternative for primary staging, especially in settings with limited PET/CT availability. The study was approved by the Swedish Ethical Review Authority (approval number 2021 - 01642) and the Swedish Medical Products Agency (EudraCT-number 2021-001059-15). Trial registration date 16th February 2022.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Saudi A, Ståhlgren M, Takhar P, et al. Head-to-head comparison of 99mTc-MIP-1404 CZT SPECT/CT and 68Ga/PSMA-11 PET/CT for primary staging of high-risk prostate cancer: a phase II study. EJNMMI Res. 2026. PMID: 42489957. doi:10.1186/s13550-026-01479-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。